Black Diamond Therapeutics: Market Is Yawning About These Data, But I See OpportunitySeeking Alpha • 03/25/26
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/16/26
Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 01/23/26
Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX)Zacks Investment Research • 12/04/25
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBMGlobeNewsWire • 12/03/25
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program UpdateGlobeNewsWire • 12/02/25
Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run?Zacks Investment Research • 11/12/25
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/06/25
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?Zacks Investment Research • 10/22/25
Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue?Zacks Investment Research • 10/07/25
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?Zacks Investment Research • 09/25/25
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?Zacks Investment Research • 09/23/25
Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 09/22/25